CME Group Inc (CME) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CME Group Inc stock (CME) is currently trading at $293.93. CME Group Inc PE ratio is 26.31. CME Group Inc PS ratio (Price-to-Sales) is 16.24. Analyst consensus price target for CME is $306.86. WallStSmart rates CME as Hold.
CME Group Inc (CME) stock price prediction for 2030: Base case $230.89. Bull case $288.61. Bear case $173.17. See full CME 2030 price forecast and methodology on WallStSmart.
- CME PE ratio analysis and historical PE chart
- CME PS ratio (Price-to-Sales) history and trend
- CME intrinsic value — DCF, Graham Number, EPV models
- CME stock price prediction 2025 2026 2027 2028 2029 2030
- CME fair value vs current price
- CME insider transactions and insider buying
- Is CME undervalued or overvalued?
- CME Group Inc financial analysis — revenue, earnings, cash flow
- CME Piotroski F-Score and Altman Z-Score
- CME analyst price target and Smart Rating
CME Group Inc
📊 No data available
Try selecting a different time range
CME Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · CME Group Inc (CME)
CME trades at a significant discount to its Graham intrinsic value of $522.76, offering a 44% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
CME Group Inc (CME) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, eps growth. Concerns around peg ratio and price/sales. Fundamentals are solid but monitor weak areas for improvement.
CME Group Inc (CME) Key Strengths (5)
Keeps $64 of every $100 in revenue after operating costs
Earnings per share surging 35.00% year-over-year
Keeps $63 of every $100 in revenue as net profit
91.51% of shares held by major funds and institutions
Large-cap company with substantial market presence
CME Group Inc (CME) Areas to Watch (5)
Very expensive relative to growth, significant premium
Very expensive at 16.2x annual revenue
Premium pricing at 3.8x book value
Modest revenue growth at 8.00%
Moderate profitability with room for improvement
Supporting Valuation Data
CME Group Inc (CME) Detailed Analysis Report
Overall Assessment
This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, EPS Growth, Profit Margin. Profitability is solid with Operating Margin at 63.80%, Profit Margin at 62.60%. Growth metrics are encouraging with EPS Growth at 35.00%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (5.84), Price/Sales (16.24), Price/Book (3.84) suggest expensive pricing. Growth concerns include Revenue Growth at 8.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 14.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 14.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, EPS Growth) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CME Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CME's Price-to-Sales ratio of 16.24x trades 38% below its historical average of 26.21x (54th percentile). The current valuation is 86% below its historical high of 117.92x set in Dec 2007, and 196% above its historical low of 5.48x in Jul 2012.
WallStSmart Analysis Synopsis
Data-driven financial summary for CME Group Inc (CME) · FINANCIAL SERVICES › FINANCIAL DATA & STOCK EXCHANGES
The Big Picture
CME Group Inc is a mature, profitable business with steady cash generation. Revenue reached 6.5B with 8% growth year-over-year. Profit margins are strong at 62.6%, reflecting pricing power and operational efficiency.
Key Findings
Profit margin of 62.6% and operating margin of 63.8% demonstrate strong pricing power and operational efficiency.
Generating 1.1B in free cash flow and 1.1B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor FINANCIAL DATA & STOCK EXCHANGES industry trends, competitive moves, and regulatory changes that could impact CME Group Inc.
Bottom Line
CME Group Inc is a well-established business delivering consistent profitability with 62.6% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(37 last 3 months)
| Insider | Type | Shares |
|---|---|---|
VROMAN, KEN Chief Transformation Officer | Sell | -5,160 |
| Insider | Type | Shares |
|---|---|---|
TOBIN, JACK J MD Chief Accounting Officer | Sell | -105 |
| Insider | Type | Shares |
|---|---|---|
COOK, ELIZABETH A Director | Sell | -1,000 |
| Insider | Type | Shares |
|---|---|---|
DURKIN, BRYAN T Director | Sell | -4,200 |
| Insider | Type | Shares |
|---|---|---|
GEPSMAN, MARTIN J Director | Sell | -300 |
| Insider | Type | Shares |
|---|---|---|
SUSKIND, DENNIS Director | Sell | -748 |
| Insider | Type | Shares |
|---|---|---|
DUFFY, TERRENCE A Director, Chairman and CEO | Sell | -10,210 |
Data sourced from SEC Form 4 filings
Last updated: 2:28:44 PM
About CME Group Inc(CME)
NASDAQ
FINANCIAL SERVICES
FINANCIAL DATA & STOCK EXCHANG...
USA
CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.